E-Buy Home Stock Price, News & Analysis

E-BUY HOME INC (OTC: EBYH), now doing business as Strainsforpains, Inc., is described in company communications as an innovative healthcare data technology company focused on the intersection of medical cannabis, wellness, and artificial intelligence. The company states that it is located in New York, New York, and that it operates a multi-faceted business built around cannabinoid-based products and a proprietary healthcare application.

According to multiple corporate updates, Strainsforpains’ core objective is to provide doctors, nurses, dispensaries, and patients with access to an app that allows for an advanced determination and comparison of cannabis strains or brands and cannabinoid combinations with major illnesses in a user-friendly manner. The company reports that this app is being upgraded to incorporate advanced artificial intelligence, with the goal of collaborating with pain management departments at hospitals and healthcare professionals, and expanding the selection of cannabis varietals for therapeutic use.

Healthcare Data Technology and AI-Driven App

Strainsforpains describes its primary technology asset as a proprietary healthcare app that functions as a medical marijuana recommendation engine. In public interviews and press releases, the company explains that the app is built on a database of cannabis strains, cannabinoids, and medicinal applications, and that it uses advanced algorithms and artificial intelligence to guide patients and professionals toward cannabinoid levels, strains, and consumption methods aligned with specific ailments.

The company states that the app is intended to support pain management operations at hospitals and with doctors specializing in pain relief. It is described as an educational tool that aims to close the information gap between patients and hospitals by providing real-time AI-integrated tools to assess categorized ailments, patient information, and therapeutic cannabis options. Corporate communications also reference proprietary algorithms that enable healthcare professionals to analyze patient data and predict optimal cannabis products and dosages for individual outcomes.

CBD Product Line and Pennsylvania Facility

Alongside its data technology activities, Strainsforpains reports that it is active in the CBD market. Company updates describe a product line that includes topical CBD body creams and plans for ingestible CBD products. The company notes that it has secured distribution orders from pharmacies, wellness centers, CBD and health markets, and dispensaries in the New York City and Tri-State area, and that it has collaborated with distributors and partners to expand its retail reach.

Strainsforpains states that it owns a facility in Pennsylvania, described in various releases as a 6.5- to 7-acre property, which is intended to be used for CBD product production and storage. The company reports that it has increased the capacity of this facility to accommodate a growing CBD product line and has discussed leasing part of the property for a local data center. Corporate statements also mention product storage at both the Pennsylvania facility and New York City locations as part of its supply chain.

Partnerships, Collaborations, and Research Focus

Company news releases highlight a series of partnerships and collaborations. Strainsforpains reports strategic relationships with hemp farmers and distributors in Virginia and Pennsylvania to support a resilient and optimized supply chain for its CBD products. It also describes a licensing and partnership arrangement with GenBio, a biotech research company focused on developing next-generation anti-inflammatory drugs and nutraceuticals based on natural extracts, with the intention of incorporating these compounds into Strainsforpains-branded CBD products.

Strainsforpains further reports a joint venture and commercialization agreement with Cannabis Science, Inc. relating to cannabinoid-based drug development, including references to Harvard award-recognized cancer research associated with Cannabis Science. Company communications state that this collaboration is intended to support commercialization of cannabinoid drugs for critical ailments and to integrate Strainsforpains’ AI medical technology with Cannabis Science’s product pipeline.

In addition, the company describes collaborations with medical institutions such as Mt. Sinai in New York City and Johns Hopkins in Baltimore. According to its statements, these collaborations are focused on merging advanced AI data integrations and interactions into its proprietary cannabinoid healthcare app, with an emphasis on professional analytics for multiple indications and critical ailments in pain management and other therapeutic areas.

Events, Media, and Awareness Initiatives

Strainsforpains’ public communications also describe involvement in awareness and fundraising initiatives connected to cancer treatment and cannabinoid research. The company reports an alliance with the “1-Million Strong Killing Cancers, Fight Club” (1MSFC), which is presented as a live MMA fight series and broader media initiative designed to support fundraising for low-cost cancer drug development associated with Cannabis Science. Company releases discuss plans for televised MMA events, concerts, fashion shows, and other live events intended to promote cancer-related initiatives and expand distribution channels for cannabinoid products.

Strainsforpains also references plans for podcasts, television content, and other media platforms featuring expert insights and discussions about cannabis and wellness. These initiatives are described as part of a broader effort to build brand recognition, support education around medical cannabis, and highlight the company’s role in health and wellness.

Corporate Identity and Ticker

In multiple news releases, the company identifies itself as Strainsforpains, Inc. (OTC: EBYH), fka/ E-Buy Home Inc. The communications indicate that Strainsforpains is progressing toward completing an audit to become fully reporting, changing its symbol, and building the revenues and asset base it associates with a potential uplisting. The ticker EBYH is therefore linked in company materials to Strainsforpains’ healthcare data technology and cannabinoid-focused operations.

Business Focus Summary

Based on its public statements, Strainsforpains’ business model centers on:

• Developing and enhancing a proprietary AI-driven healthcare app for medical cannabis strain and cannabinoid recommendations.
• Commercializing CBD products, including topical creams and planned ingestible products, supported by a Pennsylvania production facility and regional distribution partners.
• Collaborating with research institutions and biotech partners on cannabinoid science, anti-inflammatory compounds, and potential therapeutic applications.
• Participating in media and event-based initiatives related to cancer awareness and cannabinoid drug development in conjunction with partners.

All of these elements are described by the company in its own news releases and interviews as part of its strategy in the health, wellness, and medical cannabis sectors.